IRWD - アイアンウッド・ファ―マシュ―ティカルズ （Ironwood Pharmaceuticals Inc.） アイアンウッド・ファ―マシュ―ティカルズIRWDのチャート
IRWDの企業情報
| symbol | IRWD |
|---|---|
| 会社名 | Ironwood Pharmaceuticals Inc （アイアンウッド・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイアンウッド・ファーマシューティカルス（Ironwood Pharmaceuticals Inc.）はバイオテクノロジー企業である。同社は便秘過敏性腸症候群（IBS C）、慢性特発性便秘（CIC）、制御不能な痛風に関連する高尿酸血症、制御不能な胃食道逆流症（無制御性GERD）、血管および線維症等の分野の製品を開発する。同社は人体治療事業セグメントを運営する。同社の製品リナクロチドは「LINZESS」という商標名で米国のIBS CまたはCICに罹患している成人男性および女性に可能でき、商標名「CONSTELLA」で特定のヨーロッパ諸国のIBS Cに罹患している成人男性および女性に利用可能である。同社はまた、GERDを有する患者において対症的軽減をもたらす可能性のある胆汁酸封鎖剤の胃保持製剤IW-3718を開発する。血管・線維プログラムには可溶性グアニル酸シクラーゼ（sGC）を標的とするIW-1973およびIW-1701が含まれる。 アイアンウッド・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。消化器・循環器系疾患、疼痛、炎症などの治療薬の発見、開発、商業化に従事。主要製品には、成人の便秘を伴う慢性特発性便秘と過敏性腸症候群の治療薬「リンゼス」（リナクロチド）がある。欧州連合(EU)においての、この治療薬の商標名は「コンステラ」。本社はマサチュ―セッツ州。 Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). |
| 本社所在地 | 301 Binney Street Cambridge MA 02142 USA |
| 代表者氏名 | Peter M. Hecht Peter M. Hecht |
| 代表者役職名 | Chief Executive Officer Director 最高経営責任者（CEO） |
| 電話番号 | +1 617-621-7722 |
| 設立年月日 | 35796 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 730人 |
| url | www.ironwoodpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/irwd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -46.26500 |
| 終値（lastsale） | 17.89 |
| 時価総額（marketcap） | 2739986136.46 |
| 時価総額 | 時価総額（百万ドル） 2559.26 |
| 売上高 | 売上高（百万ドル） 331.29400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2785.16 |
| 当期純利益 | 当期純利益（百万ドル） -112.73600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ironwood Pharmaceuticals Inc. revenues increased 28% to $150.3M. Net loss decreased 4% to $92.5M. Revenues reflect Collaborative arrangements revenue increase of 15% to $134.3M Product revenue net increase from $754K to $1.7M. Lower net loss reflects loss decrease of 71% to $2.5M (expense) Loss on extinguishment of debt decrease from $2M (expense) to $0K. |
IRWDのテクニカル分析
IRWDのニュース
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q2 2022 Results - Earnings Call Transcript 2022/08/06 07:17:04 Seeking Alpha
Ironwood Pharmaceuticals, Inc. (NASDAQ:NASDAQ:IRWD) Q2 2022 Earnings Conference Call August 4, 2022 08:30 a.m.
Ironwood Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:IRWD) 2022/08/05 10:50:51 Seeking Alpha
The following slide deck was published by Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals reports Q2 earnings miss; reaffirms FY22 guidance 2022/08/04 11:32:06 Seeking Alpha
Ironwood Pharmaceuticals press release (IRWD): Q2 Non-GAAP EPS of $0.21 misses by $0.09.Revenue of $97.23M (-6.5% Y/Y) misses by $6.28M.Adjusted EBITDA was $56.0 million in the…
Ironwood Pharmaceuticals Q2 2022 Earnings Preview (NASDAQ:IRWD) 2022/08/03 16:57:00 Seeking Alpha
Ironwood Pharmaceuticals (IRWD) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is $0.30 (-11.8% Y/Y) and the…
Ironwood Pharmaceuticals Breaks Below 200-Day Moving Average 2022/07/29 21:56:11 Nasdaq
In trading on Friday, shares of Ironwood Pharmaceuticals Inc (Symbol: IRWD) crossed below their 200 day moving average of $11.79, changing hands as low as $11.05 per share. Ironwood Pharmaceuticals Inc shares are currently trading off about 7.9% on the day. The chart below sh
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q2 2022 Results - Earnings Call Transcript 2022/08/06 07:17:04 Seeking Alpha
Ironwood Pharmaceuticals, Inc. (NASDAQ:NASDAQ:IRWD) Q2 2022 Earnings Conference Call August 4, 2022 08:30 a.m.
Ironwood Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:IRWD) 2022/08/05 10:50:51 Seeking Alpha
The following slide deck was published by Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals reports Q2 earnings miss; reaffirms FY22 guidance 2022/08/04 11:32:06 Seeking Alpha
Ironwood Pharmaceuticals press release (IRWD): Q2 Non-GAAP EPS of $0.21 misses by $0.09.Revenue of $97.23M (-6.5% Y/Y) misses by $6.28M.Adjusted EBITDA was $56.0 million in the…
Ironwood Pharmaceuticals Q2 2022 Earnings Preview (NASDAQ:IRWD) 2022/08/03 16:57:00 Seeking Alpha
Ironwood Pharmaceuticals (IRWD) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is $0.30 (-11.8% Y/Y) and the…
Ironwood Pharmaceuticals Breaks Below 200-Day Moving Average 2022/07/29 21:56:11 Nasdaq
In trading on Friday, shares of Ironwood Pharmaceuticals Inc (Symbol: IRWD) crossed below their 200 day moving average of $11.79, changing hands as low as $11.05 per share. Ironwood Pharmaceuticals Inc shares are currently trading off about 7.9% on the day. The chart below sh
Ironwood Pharmaceuticals Inc. (IRWD) Has Recovered 10.43% From Its Low: Is This The Beginning Of A Trend? 2022/06/17 19:00:00 Stocks Register
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) price on Friday, June 17, rose 0.35% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $11.31. A look at the stock’s price movement, the level at last check in today’s session was $11.27, moving within a range at $11.16 and $11.55. The beta … Ironwood Pharmaceuticals Inc. (IRWD) Has Recovered 10.43% From Its Low: Is This The Beginning Of A Trend? Read More »
Ironwood Pharmaceuticals Inc.’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead 2022/06/07 18:00:00 Stocks Register
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) traded at $12.15 at last check on Tuesday, June 07, made an upward move of 1.21% on its previous day’s price. Looking at the stock we see that its previous close was $12.00 and the beta (5Y monthly) reads 1.18 with the day’s price range being $11.951 – $12.44. The company … Ironwood Pharmaceuticals Inc.’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead Read More »
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week (DDW) 2022 2022/05/25 11:30:00 Wallstreet:Online
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week (DDW) meeting that suggest colonic IW-3300 has the potential to help manage abdominopelvic visceral pain in patients with disorders of gut-brain interaction (DGBI) and related visceral pain disorders. The oral presentation, titled Colon-Targeted Delivery
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week 2022 2022/05/09 12:00:00 Wallstreet:Online
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week (DDW) 2022 meeting being held from May 21 through May 24, 2022 in San Diego, CA. One oral presentation will discuss the impact of novel guanylate cyclase-C agonist
Companies - Ironwood Pharmaceuticals Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS 2022/05/08 17:17:11 Business Mag
Ironwood Pharmaceuticals released its earnings results on Thursday. The biotechnology company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.31 by…